Peptides Simplified

From insulin and GLP-1 agonists to the gray market — a clear-eyed guide to peptide medicine. Peptide medicine is in the middle of its most consequential decade since insulin. Semaglutide and tirzepatide have reshaped how diabetes and obesity are managed, while a parallel market of unapproved compounds — BPC-157, TB-500, CJC-1295, and others — has built up alongside the approved drugs without ever passing through the trials that would justify the claims made for them. This book explains both worlds in language a careful general reader can follow, with every nontrivial claim sourced to a real reference. Five parts cover the chemistry, the approved drug landscape, the GLP-1 revolution, an honest assessment of unapproved peptides, practical pharmacology, safe self-administration of prescribed peptides, and the macroeconomics of the field. By Fady Hannah-Shmouni, MD FRCPC — Clinical Endocrinologist & Geneticist, Founder & CEO of Hormonaly.ai.